Answers are grounded in this paper and cite their sources.
Background: Endometrial cancer remains a therapeutic challenge, particularly in advanced and recurrent cases. This study investigated the anticancer effects of three synthetic CDDO derivatives, RTA 404, RTA dh404, and RTA 408, in human endometrial cancer Ishikawa cells. Methods: Cell viability was assessed using the CCK-8 assay, while Ki67 expression, apoptosis, cell cycle distribution, mitochondrial membrane potential, and intracellular reactive oxygen species (ROS) levels were evaluated using immunofluorescence staining and flow cytometry-based assays. Results: All three CDDO derivatives reduced the viability-associated metabolic activity of Ishikawa cells and were associated with changes in Ki67 positivity, apoptosis, and cell cycle distribution. RTA 404 and RTA dh404 increased the proportion of cells in the G1 phase, whereas RTA 408 increased the G2/M-phase population. In addition, treatment with the compounds was associated with reduced mitochondrial membrane potential and decreased intracellular ROS-associated fluorescence. Conclusion: These findings demonstrate that treatment with RTA 404, RTA dh404, and RTA 408 is associated with reduced viability-associated metabolic activity, increased Annexin V positivity, altered cell-cycle distributions, and mitochondrial depolarization in Ishikawa endometrial cancer cells. Further mechanistic studies are required to determine the molecular pathways underlying these cellular responses.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: